DPP4 and type 2 diabetes mellitus: Instead, there is a particular interest in the use of dipeptidyl peptidase 4 (DPP-4) inhibitors in hospitalized patients with type 2 diabetes for their few side effects and neutral effects on major adverse cardiovascular outcomes [3, 5, 11–15].